These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28459962)

  • 1. Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.
    Espay AJ; Lang AE
    JAMA Neurol; 2017 Jun; 74(6):633-634. PubMed ID: 28459962
    [No Abstract]   [Full Text] [Related]  

  • 2. Agonists versus levodopa in PD: the thrilla of whitha.
    Montgomery EB
    Neurology; 2003 Nov; 61(10):1462; author reply 1462-3. PubMed ID: 14638991
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Stathis P; Konitsiotis S; Antonini A
    Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off spells and dyskinesias: pharmacologic management of motor complications.
    Khan TS
    Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations.
    Chouza C; Buzó R; Scaramelli A; Romero S; de Medina O; Aljanati R; Dieguez E; Lisanti N; Gomensoro J
    J Neural Transm Suppl; 2006; (70):427-31. PubMed ID: 17017563
    [No Abstract]   [Full Text] [Related]  

  • 7. Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.
    Marek K; Jennings D; Seibyl J
    Neurology; 2003 Sep; 61(6 Suppl 3):S43-8. PubMed ID: 14504379
    [No Abstract]   [Full Text] [Related]  

  • 8. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Parkinson disease].
    Moore AP; Clarke CE
    Praxis (Bern 1994); 2001 Jun; 90(23):1041-6. PubMed ID: 11447724
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
    Vidal EI; Fukushima FB; Valle AP; Villas Boas PJ
    J Am Geriatr Soc; 2013 Jan; 61(1):170-2. PubMed ID: 23311565
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective strategies in the management of Parkinson's disease.
    Wills AJ
    Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa strengths and weaknesses.
    Jankovic J
    Neurology; 2002 Feb; 58(4 Suppl 1):S19-32. PubMed ID: 11909982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic hypersensitivity in patients with Parkinson disease and migraine.
    Cubo E; Kompoliti K; Leurgans SE; Raman R
    Clin Neuropharmacol; 2004; 27(1):30-2. PubMed ID: 15090934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.